DIGIVESTASI - PT Indofarma Tbk (INAF), a state-owned pharmaceutical company, provided an explanation regarding the steps that will be taken after the homologation decision of the Postponement of Debt Payment Obligations (PKPU). Management stated that the company will pay off debts to creditors through the sale of some of its assets, without restructuring debt with a debt-to-share conversion scheme.

President Director of Indofarma, Yeliandriani, explained that funds to pay off obligations to creditors will be obtained from the sale of collateral assets, both production and non-production, which have an appraisal value of IDR 865.83 billion. In addition, the sale of non-guaranteed assets with an appraisal value of Rp 88.64 billion and remaining cash from restricted operating activities will also be used to pay off the debt.

Management added that the assets to be sold are land and buildings, with an appraised value of IDR 954.46 billion based on the 2024 valuation of the Public Appraisal Services Office (KJPP). The sale of these assets is sought to use the appraisal value as the minimum sales price to mitigate the company's losses.

The implementation of the sale of non-guaranteed assets will begin after the effective date of homologation, with the first offer to investors, strategic partners, or other third parties. If within two months this sale does not take place, the company will offer the assets to creditors who provided working capital.

Debts will be repaid in the order of payment agreed in the settlement agreement with creditors, as soon as the proceeds from the sale of assets are received.

Find more news and articles on Google News